99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows
99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows
On Wednesday, Eli Lilly And Co (NYSE:LLY) released detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed study to date of tirzepatide.
礼来周三发布了第3期SURMOUNt-1三年研究(176周治疗期)的详细结果，这是迄今为止完成时间最长的提泽帕肽研究。
Weekly tirzepatide (Zepbound and Mounjaro) injections (pooled 5 mg, 10 mg, 15 mg doses) significantly reduced the risk of progression to type 2 diabetes in adults with pre-diabetes and obesity or overweight, compared with placebo, over 176 weeks.
每周注射 tirzepatide（Zepbound 和 Mounjaro）（合并 5 mg、10 mg、15 mg 剂量）在176周内显著减少了患有糖尿病前期和肥胖或超重的成年人发展为2型糖尿病的风险，与安慰剂相比。
Tirzepatide demonstrated sustained average weight loss of 22.9% (15 mg dose) through the three-year treatment period for the efficacy estimandi.
tirzepatide 在三年的治疗期间（15 mg 剂量）表现出持续的平均体重下降 22.9%。
Also Read: Eli Lilly Q3 Earnings: Mounjaro Sales More Than Double, Takes $2.98 Billion Hit To Profit, Cuts Annual Outlook, Stock Tanks
另请阅读：礼来第三季度财报：Mounjaro 销售额超过翻倍，利润受到 29.8亿 美元的打击，下调年度展望，股票大跌。
"Individuals treated with tirzepatide lost on average up to 23% of their body weight and maintained this for over three years while benefitting from a substantial decrease in risk of developing type 2 diabetes. In absolute terms, nearly 99% of individuals treated with tirzepatide remained diabetes-free at 176 weeks," said Ania Jastreboff, director of the Yale Obesity Research Center.
“接受 tirzepatide 治疗的个体平均体重减少了 23%，并在三年内维持这一水平，同时显著降低了发展为2型糖尿病的风险。在绝对值上，近 99% 的接受 tirzepatide 治疗的个体在 176 周时仍然没有患糖尿病，”耶鲁大学肥胖研究中心的董事 Ania Jastreboff 说。
"In the SURMOUNT-1 three-year study of tirzepatide, an average weight reduction of up to 22.9% was accompanied by a hazard ratio of 0.06 for progression to type 2 diabetes. This translates to a risk reduction of 94% and a number needed to treat of nine to prevent one case of diabetes," said Jeff Emmick, SVP of product development at Eli Lilly.
“在 tirzepatide 的 SURMOUNt-1 三年研究中，平均体重降低高达 22.9%，伴随发展为2型糖尿病的危险比为 0.06。这转化为94%的风险降低，以及需要治疗九人以预防一例糖尿病，”礼来产品开发高级副总裁 Jeff Emmick 说。
At 193 weeks, 2.4% of patients on Lilly's tirzepatide were diagnosed with Type 2 diabetes compared to 13.7% of patients in the placebo group.
在 193 周时，使用礼来的 tirzepatide 的患者中 2.4% 被诊断为2型糖尿病，而安慰剂组的患者中则为 13.7%。
In additional endpoints, the study showed an association of tirzepatide treatment with improved glycemic control, cardiometabolic risk factors (including fasting insulin, blood pressure, and lipids), and health-related quality of life sustained through 176 weeks.
在其他终点上，研究显示 tirzepatide 治疗与改善糖代谢控制、心脏代谢风险因素（包括空腹胰岛素、血压和血脂）以及持续 176 周的健康相关生活质量有关。
A post hoc mediation analysis suggested that approximately half of the observed effect in a delay to onset of type 2 diabetes with tirzepatide was associated with medication-induced weight reduction.
后验中介分析表明，约一半观察到的tirzepatide延缓2型糖尿病发作的效果与药物诱导的体重减轻有关。
Price Action: LLY stock is down 2.21% at $793.97 at the last check on Thursday.
价格动态：礼来股票在周四最后一次检查时下跌2.21%，报$793.97。
- Salesforce CEO Marc Benioff Bets Big on Billion Bots
- 赛富时CEO马克·贝尼奥夫大举投资于数十亿个机器人
Image by Mohammed_Al_Ali via Shutterstock
图片来自Shutterstock的Mohammed_Al_Ali。
